cas 6994-25-8|| where to buy ethyl 3-amino-1H-pyrazole-4-carboxylate

Nom du produit:ethyl 3-amino-1H-pyrazole-4-carboxylate

IUPAC Name:ethyl 3-amino-1H-pyrazole-4-carboxylate

Unité d'emballage	Stock disponible	Prix($)
CM104625-100g	in stock	ȅŸ
CM104625-500g	in stock	ŸŪȖ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 6994-25-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:6994-25-8; Formule moléculaire:C6H9N3O2; Point de fusion:-; Code SMILES:CCOC(=O)C1=CNN=C1N; Densité:

: Numéro de catalogue:CM104625; Poids moléculaire:155.16; Point d'ébullition:349.2°C at 760 mmHg; N° Mdl:MFCD00005238; Stockage:Keep in dark place, store at 2-8°C.

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: Repotrectinib; Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.